OCEA vs. TRVN, VINC, SYRS, OBSV, SCPS, VRPX, STAB, EVLO, CMRA, and AMPE
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Trevena (TRVN), Vincerx Pharma (VINC), Syros Pharmaceuticals (SYRS), ObsEva (OBSV), Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical preparations" industry.
Ocean Biomedical vs. Its Competitors
Trevena (NASDAQ:TRVN) and Ocean Biomedical (NASDAQ:OCEA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.
In the previous week, Trevena's average media sentiment score of 0.00 equaled Ocean Biomedical'saverage media sentiment score.
13.6% of Trevena shares are owned by institutional investors. Comparatively, 24.6% of Ocean Biomedical shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 73.5% of Ocean Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Trevena has higher revenue and earnings than Ocean Biomedical. Trevena is trading at a lower price-to-earnings ratio than Ocean Biomedical, indicating that it is currently the more affordable of the two stocks.
Trevena presently has a consensus price target of $5.00, indicating a potential upside of 1,900.00%. Given Trevena's stronger consensus rating and higher probable upside, equities analysts plainly believe Trevena is more favorable than Ocean Biomedical.
Trevena has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Ocean Biomedical has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Summary
Trevena and Ocean Biomedical tied by winning 5 of the 10 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OCEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:OCEA) was last updated on 9/8/2025 by MarketBeat.com Staff
